When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

The headline numbers for Biogen (BIIB) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

The headline numbers for Helmerich & Payne (HP) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Although the revenue and EPS for nVent (NVT) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Although the revenue and EPS for Roblox (RBLX) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

While the top- and bottom-line numbers for Centene (CNC) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Although the revenue and EPS for Insight Enterprises (NSIT) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

The headline numbers for F5 (FFIV) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Ernest Hoffman is a Crypto and Market Reporter for Kitco News. He has over 15 years of experience as a writer, editor, broadcaster and producer for media, educational and cultural organizations.

THC, UHS and OPCH look poised to beat Q4 estimates as volumes, admissions and revenue trends improve.

BCE posts lower Q4 2025 EPS and revenue as product sales slide, but service growth, Ziply Fiber gains and a dividend highlight its long-term cash flow focus.

Covista emerges from ATGE's healthcare-focused overhaul, positioning itself as workforce infrastructure aimed at easing America's medical staffing shortage.

CUZ posts Q4 FFO of $0.71, in line with estimates, as revenues jump and leasing stays healthy. Occupancy slips, and interest costs rise.

The recent 10% drop in Micron Technology (MU) to roughly $370 has sparked a significant discussion: is this an ideal entry point into an AI-powered supercycle or a fundamental decline due to fierce competition? While the wider semiconductor downturn was triggered by a "momentum break" and technical fatigue, Micron's specific trajectory is guided by its struggle for supremacy in High-Bandwidth Memory (HBM).

PLEASANTON, Calif., Feb. 6, 2026 /PRNewswire/ -- Healthcare Triangle, Inc. (Nasdaq: HCTI) ("HCTI" or the "Company"), a leader in digital transformation solutions including managed services, cloud enablement, and data analytics for the healthcare and life sciences industry, today announced that it will effect a 1-for-60 reverse stock split of its common stock.

Strategy (NASDAQ:MSTR) shares surged on Friday following the release of the company's fourth quarter earnings report, which showed solid growth in its software and subscription business offset by a massive accounting-driven loss tied to its Bitcoin holdings. Total revenue for Q4 came in at $123 million, up roughly 2% year over year and above the Wall Street consensus of around $119 million, reflecting strength in the company's higher-margin subscription and license revenue.

RBC Capital Markets has downgraded Shell PLC to 'Sector Perform' from 'Outperform', citing mounting concerns over the energy major's resource depth and what the bank calls a rare "double miss" on earnings. The investment bank cut its price target to 3,200p from 3,600p, implying roughly 12% upside from current levels.

CRDO's shares slid nearly 32% in a month, but strong AI networking demand, rising margins and a solid balance sheet argue for patience.

Orange County Bancorp, Inc. (OBT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Examine the evolution of F5's (FFIV) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.